Indigenous pharmaceutical manufacturer, Miraflash Nigeria Limited, has inaugurated a new board of directors comprising distinguished pharmaceutical industry experts and seasoned technocrats as part of a strategic move to strengthen corporate governance and accelerate the company’s next phase of growth.
The Managing Director and Chief Executive Officer of the company, Pharm. (Dr) Moses Olurotimi Oluwalade, said the board was carefully constituted to provide strategic direction, deepen innovation and position Miraflash as one of Nigeria’s leading pharmaceutical manufacturers capable of competing effectively in both local and international markets.
Sitting as the chairman of the Miraflash board is a former managing director and current chairman of NEM Insurance, Dr Tope Smart. Other members of the board are a former managing director of Pfizer products, Pharm. Yinka Subair; the group managing director of Berger Paints Nigeria PLC, Mrs Alaba Fagun; Mr Afinju Taiwo, FCA; a former medical director, Chevron Clinic, Dr Peter Ajayi; and Mr Murtala Gbadamosi, FCA.
According to Dr Oluwalade, the inauguration of the board marks a significant milestone in the evolution of the company, reflecting its determination to build a resilient institution driven by professionalism, innovation and sustainable growth.
“The objective is to move the company to the next level. We are bringing together experienced professionals with proven records in pharmaceutical manufacturing, corporate governance and business management to strengthen our capacity and position Miraflash for greater impact in Nigeria’s healthcare sector,” he said.
Founded in 2005, Miraflash Nigeria Limited has grown into one of Nigeria’s foremost indigenous pharmaceutical manufacturers, with its production facility located in Magboro, Ogun State. The company received regulatory approvals from the National Agency for Food and Drug Administration and Control (NAFDAC) and the Pharmacy Council of Nigeria (PCN) before commencing commercial production and has since established itself as a trusted manufacturer of quality medicines.
Initially focused on dry powder antibiotic suspensions, the company has steadily expanded its manufacturing capacity to include capsules. Today, Miraflash is widely recognised as a specialist in the production of beta-lactam cephalosporin antibiotics with more than 20 pharmaceutical products in its portfolio.
Its product range includes Miraxim (cefuroxime) capsules and suspension, Mospodox (cefpodoxime) capsules and oral suspension, Mirafix (cefixime) capsules and suspension, Fladinir capsules, Cephaflash suspension, Miradroxil, Cephaflash, Tridermix-G cream, and Mirapain cream, among other prescription medicines used in the treatment of bacterial infections and dermatological conditions. All of these products are registered with NAFDAC and continue to serve healthcare providers and patients across the country.
Oluwalade noted that quality assurance remains one of the defining pillars of the company, saying every stage of its manufacturing process, from sourcing raw materials to production, quality control and packaging, is guided by current Good Manufacturing Practice (cGMP).
The company’s vision is “to improve and raise the bar of the length and quality of life by delivering compelling customer care and ensuring high-quality product availability”, and on a mission “to produce and provide affordable and consistently high-quality pharmaceutical products and medicare for a healthy life for those it’s serving.”
According to the MD/CEO, with an experienced board, expanding product portfolio and renewed commitment to quality, innovation and affordability, Miraflash Nigeria Limited is set to consolidate its position in Nigeria’s pharmaceutical industry while contributing significantly to improved access to quality healthcare and supporting the Federal Government’s drive for self-sufficiency in medicine production.
